Barclays PLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Barclays PLC raised its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 32.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 494,516 shares of the company’s stock after buying an additional 121,799 shares during the quarter. Barclays PLC’s holdings in Mersana Therapeutics were worth $934,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MRSN. State Street Corp raised its holdings in shares of Mersana Therapeutics by 1.6% during the 3rd quarter. State Street Corp now owns 2,725,394 shares of the company’s stock worth $5,151,000 after acquiring an additional 43,339 shares during the period. Renaissance Technologies LLC increased its position in Mersana Therapeutics by 1.4% during the second quarter. Renaissance Technologies LLC now owns 1,448,219 shares of the company’s stock worth $2,911,000 after purchasing an additional 20,400 shares during the last quarter. Verition Fund Management LLC raised its stake in Mersana Therapeutics by 11,695.2% during the third quarter. Verition Fund Management LLC now owns 1,303,249 shares of the company’s stock worth $2,463,000 after purchasing an additional 1,292,200 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in Mersana Therapeutics by 104.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 993,046 shares of the company’s stock valued at $1,877,000 after purchasing an additional 507,453 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Mersana Therapeutics by 16.0% in the 3rd quarter. Wellington Management Group LLP now owns 618,305 shares of the company’s stock valued at $1,169,000 after buying an additional 85,439 shares during the period. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

Mersana Therapeutics Price Performance

Shares of MRSN opened at $1.42 on Tuesday. The firm has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $1.93. The stock has a market cap of $175.42 million, a PE ratio of -2.33 and a beta of 1.40. Mersana Therapeutics, Inc. has a 1-year low of $1.22 and a 1-year high of $6.28. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm had revenue of $12.60 million during the quarter, compared to the consensus estimate of $7.53 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s revenue for the quarter was up 63.6% on a year-over-year basis. As a group, analysts forecast that Mersana Therapeutics, Inc. will post -0.61 EPS for the current year.

Analyst Ratings Changes

Separately, Citigroup began coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Mersana Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.